Unstable angina--clinical course and medical management including antiplatelet treatment.
One hundred patients with unstable angina who were treated medically were classified into 2 groups of non-crescendo and crescendo angina and reviewed regarding their clinical course for 24 months on the average. Thirty-four patients with non-crescendo angina had an occurrence of recurrent angina in 7 patients (21%), myocardial infarction in 2 (6%) and death in none, while 66 patients with crescendo angina had a significantly higher occurrence of recurrent angina in 29 (44%) and myocardial infarction in 14 (21%), p less than 0.05 in both angina and infarction. There were 4 (6%) deaths in patients with crescendo angina in spite of similar clinical backgrounds. Modern medical treatments of unstable angina include nitrates, beta blockers, calcium antagonists as well as antiplatelet and thrombolytic therapy. We conclude that our patients under active medical treatment have more favorable prognosis than once thought and that classification of unstable angina into non-crescendo and crescendo angina according to the early clinical course appears to be useful both for a selection of treatments and for an assessment of prognosis.
D000244:Adenosine Diphosphate / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D010450:Endopeptidases / Q000008:administration & dosage*; D004837:Epinephrine / Q000008:administration & dosage; D011464:Epoprostenol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage; D010974:Platelet Aggregation / Q000187:drug effects; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D000244:Adenosine Diphosphate; D011464:Epoprostenol; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator; D005996:Nitroglycerin; D004837:Epinephrine